SG11202011743SA - Fusion proteins comprising progranulin - Google Patents

Fusion proteins comprising progranulin

Info

Publication number
SG11202011743SA
SG11202011743SA SG11202011743SA SG11202011743SA SG11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA
Authority
SG
Singapore
Prior art keywords
progranulin
fusion proteins
fusion
proteins
Prior art date
Application number
SG11202011743SA
Inventor
Paolo Gilbert Di
Todd P Logan
Kathryn M Monroe
Ankita Srivastava
Lengerich Bettina Van
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of SG11202011743SA publication Critical patent/SG11202011743SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
SG11202011743SA 2018-06-18 2019-06-18 Fusion proteins comprising progranulin SG11202011743SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862686579P 2018-06-18 2018-06-18
US201862746338P 2018-10-16 2018-10-16
PCT/US2019/037695 WO2019246071A1 (en) 2018-06-18 2019-06-18 Fusion proteins comprising progranulin

Publications (1)

Publication Number Publication Date
SG11202011743SA true SG11202011743SA (en) 2021-01-28

Family

ID=67138158

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011743SA SG11202011743SA (en) 2018-06-18 2019-06-18 Fusion proteins comprising progranulin

Country Status (17)

Country Link
US (2) US20210284702A1 (en)
EP (1) EP3807322A1 (en)
JP (1) JP2021527656A (en)
KR (1) KR20210027377A (en)
CN (1) CN112424233A (en)
AU (1) AU2019288212A1 (en)
BR (1) BR112020025306A2 (en)
CA (1) CA3101202A1 (en)
CL (1) CL2020003255A1 (en)
EC (1) ECSP20081591A (en)
IL (1) IL279510A (en)
MX (1) MX2020012518A (en)
PE (1) PE20210323A1 (en)
PH (1) PH12020552189A1 (en)
SG (1) SG11202011743SA (en)
TW (1) TW202016152A (en)
WO (1) WO2019246071A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280441B1 (en) 2015-04-07 2021-09-29 Alector LLC Anti-sortilin antibodies and methods of use thereof
JP6619822B2 (en) * 2015-05-29 2019-12-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Non-human animals with disruption at the C9ORF72 locus
AU2018221731C1 (en) 2017-02-17 2021-11-18 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
MX2020002918A (en) 2017-10-02 2020-07-22 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes.
CA3060547A1 (en) 2018-07-13 2020-01-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
MX2021001711A (en) * 2018-08-16 2021-05-27 Denali Therapeutics Inc Engineered bispecific proteins.
CN114981297A (en) 2019-12-23 2022-08-30 戴纳立制药公司 Proteinogenin variants
KR20220131246A (en) 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. Anti-TREM2 antibodies and methods of use thereof
US20210393787A1 (en) * 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
JP2023542178A (en) * 2020-09-18 2023-10-05 アイユーシーエフ－エイチワイユー（インダストリー－ユニバーシティ コーオペレーション ファウンデーション ハンヤン ユニバーシティ） PTPsigma-Fc fusion protein and pharmaceutical composition containing the same
CN116420078A (en) 2020-10-14 2023-07-11 戴纳立制药公司 Methods for treating and monitoring frontotemporal dementia
IL302029A (en) 2020-10-14 2023-06-01 Denali Therapeutics Inc Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
TW202340459A (en) * 2021-12-17 2023-10-16 美商戴納立製藥公司 Fusion proteins comprising alpha-l-iduronidase enzymes and methods thereof
WO2023198661A1 (en) * 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
WO2023224956A1 (en) * 2022-05-16 2023-11-23 Denali Therapeutics Inc. Transferrin receptor-binding domains and proteins comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
EP3280441B1 (en) * 2015-04-07 2021-09-29 Alector LLC Anti-sortilin antibodies and methods of use thereof
DK3313879T3 (en) * 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrin receptor antibodies with adapted affinity
WO2018024162A1 (en) * 2016-08-03 2018-02-08 Sunshine Lake Pharma Co., Ltd. Glp-1 fusion protein comprising mutated immunoglobulin fc portion
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
WO2018152285A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Transferrin receptor transgenic models

Also Published As

Publication number Publication date
US20230406898A1 (en) 2023-12-21
JP2021527656A (en) 2021-10-14
BR112020025306A2 (en) 2021-03-09
CA3101202A1 (en) 2019-12-26
MX2020012518A (en) 2021-02-16
US20210284702A1 (en) 2021-09-16
PE20210323A1 (en) 2021-02-18
CL2020003255A1 (en) 2021-05-28
AU2019288212A1 (en) 2020-12-03
KR20210027377A (en) 2021-03-10
ECSP20081591A (en) 2021-01-29
EP3807322A1 (en) 2021-04-21
TW202016152A (en) 2020-05-01
PH12020552189A1 (en) 2021-06-28
CN112424233A (en) 2021-02-26
WO2019246071A1 (en) 2019-12-26
IL279510A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
SG11202011743SA (en) Fusion proteins comprising progranulin
IL281954A (en) Heterodimeric fc-fused proteins
EP3287470A4 (en) Novel recombinant bi-functional fusion protein and preparation and application therefor
GB201509413D0 (en) Fusion protein
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
EP3743438A4 (en) Cytokine fusion proteins
HK1246315A1 (en) Cytokine fusion proteins
EP3880814A4 (en) Fusion protein
EP3757218A4 (en) Fusion protein
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
DK3737402T3 (en) Modificeret protein
GB201504691D0 (en) Fusion protein
ZA202003845B (en) Fusion proteins
SG11202104912SA (en) Fusion protein and use thereof
SG11202110400QA (en) Fusion protein and use thereof
IL273271A (en) Fusion protein comprising an fgf-18 moiety
IL281088A (en) Flt3l-based chimeric proteins
IL281203A (en) Pneumococcal fusion protein vaccines
IL279057A (en) Endolysin-containing antimicrobial fusion proteins and uses thereof
IL273626A (en) Immunomodulatory fusion proteins
IL290660A (en) Therapeutic fusion proteins
ZA202102533B (en) Fusion protein
HK1257937A1 (en) Fusion protein
IL281132A (en) Combination therapies comprising pd-1-based chimeric proteins
ZA202007491B (en) Stable fusion protein formulation